Compare Biogen Inc (BIIB) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Kraft Heinz Co — how do they compare? Biogen Inc trades at $192.5 (market cap $28.34B), while Kraft Heinz Co trades at $24.9 (market cap $29.74B). The key difference: Biogen Inc and Kraft Heinz Co are close in size by market cap, and Kraft Heinz Co pays a 6.38% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | KHC | |
|---|---|---|
Market Cap | $28.34B | $29.74B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $28.94 |
52-Week Low | $122.68 | $21.21 |
Enterprise Value | $30.62B | $46.78B |
Dividend Yield | — | 6.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Kraft Heinz (KHC) trades at $25.23, up 1.53% with a bullish technical trend and strong recent earnings beats. The stock shows attractive valuation metrics with a P/E of 13.04 and P/B of 0.71, though profitability remains challenged with negative net income margins. Recent corporate restructuring aims to accelerate growth, while a 6.4% dividend yield provides income support. Cash flow trends have improved significantly from 2022's negative $2.4B to 2025's positive $1.46B.
The outlook remains cautious despite technical strength. While undervaluation and dividend yield offer appeal, persistent negative profitability and high debt levels pose significant risks. Analyst consensus is predominantly Hold with a $23.50 price target below current levels, suggesting limited near-term upside potential amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
